Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 3, 2006, Pages 365-385

  Tefferi, Ayalew ^a   Gilliland, Gary ^b  

^a Mayo Clinic   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

acute myeloid leukemia; Bcr Abl; chronic myeloid disorder

Indexed keywords

BCR ABL PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; JANUS KINASE INHIBITOR; LENALIDOMIDE; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; STAT3 PROTEIN; STEM CELL FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE 1;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CHRONIC MYELOID LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; CLONAL VARIATION; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; EOSINOPHILIC LEUKEMIA; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC MASTOCYTOSIS; THERAPY RESISTANCE; THROMBOCYTHEMIA;

FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 33744999628     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.07.001     Document Type: Review

References (232)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 6 (1951) 372-375
2. Dameshek W. Foreword and a proposal for considering paroxysmal nocturnal hemoglobinuria (PNH) as a 'candidate' myeloproliferative disorder. Blood 33 (1969) 263-264
3. Oni S.B., Osunkoya B.O., and Luzzatto L. Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood 36 (1970) 145-152
4. Ohashi H., Hotta T., Ichikawa A., et al. Peripheral blood cells are predominantly chimeric of affected and normal cells in patients with paroxysmal nocturnal hemoglobinuria: simultaneous investigation on clonality and expression of glycophosphatidylinositol-anchored proteins. Blood 83 (1994) 853-859
5. Takeda J., Miyata T., Kawagoe K., et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 (1993) 703-711
6. Parker C.J. Molecular basis of paroxysmal nocturnal hemoglobinuria. Stem Cells 14 (1996) 396-411
7. Bennett J.M., Catovsky D., Daniel M.T., et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British cooperative leukaemia group. British Journal of Haematology 87 (1994) 746-754
8. Bennett J.M., Brunning R.D., and Vardiman J.W. Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. Blood 99 (2002) 3074-3075
9. Fialkow P.J., Gartler S.M., and Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proceedings of the National Academy of Sciences of the USA 58 (1967) 1468-1471
10. Barr R.D., and Fialkow P.J. Clonal origin of chronic myelocytic leukemia. The New England Journal of Medicine 289 (1973) 307-309
11. Adamson J.W., Fialkow P.J., Murphy S., et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. The New England Journal of Medicine 295 (1976) 913-916
12. Fialkow P.J., Jacobson R.J., and Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. The American Journal of Medicine 63 (1977) 125-130
13. Fialkow P.J., Denman A.M., Jacobson R.J., and Lowenthal M.N. Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. The Journal of Clinical Investigation 62 (1978) 815-823
14. Jacobson R.J., Salo A., and Fialkow P.J. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51 (1978) 189-194
15. Martin P.J., Najfeld V., Hansen J.A., et al. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature 287 (1980) 49-50
16. Fialkow P.J., Faguet G.B., Jacobson R.J., et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 58 (1981) 916-919
17. Gilliland D.G., Blanchard K.L., Levy J., et al. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proceedings of the National Academy of Sciences of the USA 88 (1991) 6848-6852
18. Reeder T.L., Bailey R.J., Dewald G.W., and Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood 101 (2003) 1981-1983
19. Tefferi A., Thibodeau S.N., and Solberg Jr. L.A. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 75 (1990) 1770-1773
20. Fugazza G., Bruzzone R., Dejana A.M., et al. Cytogenetic clonality in chronic myelomonocytic leukemia studied with fluorescence in situ hybridization. Leukemia 9 (1995) 109-114
21. Flotho C., Valcamonica S., Mach-Pascual S., et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 13 (1999) 32-37
22. Pardanani A., Reeder T., Li C.Y., and Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leukemia Research 27 (2003) 883-885
23. Yavuz A.S., Lipsky P.E., Yavuz S., et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c- kit gene. Blood 100 (2002) 661-665
24. Froberg M.K., Brunning R.D., Dorion P., et al. Demonstration of clonality in neutrophils using FISH in a case of chronic neutrophilic leukemia. Leukemia 12 (1998) 623-626
25. Pardanani A.D., Morice W.G., Hoyer J.D., and Tefferi A. Chronic basophilic leukemia: a distinict clinico-pathologic entity?. European Journal of Haematology 71 (2003) 18-22
26. Bain B.J. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. British Journal of Haematology 122 (2003) 173-179
27. Nowell P.C., and Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Journal of the National Cancer Institute 25 (1960) 85
28. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. The New England Journal of Medicine 348 (2003) 1201-1214
29. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet 365 (2005) 1054-1061
30. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature; in press.
31. Kralovics R., Passamonti F., Buser A.S., et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. The New England Journal of Medicine 352 (2005) 1779-1790
32. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
33. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in Polycythemia vera. The Journal of Biological Chemistry (2004)
34. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'Atypical' myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005. Blood first edition paper, prepublished online April 28, 2005; DOI: 10.1182/blood-2005-03-1183.
35. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005. Blood first edition paper, prepublished online May 26, 2005; DOI: 10.1182/blood-2005-03-1320.
36. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). WHO classification of tumors: tumors of the hematopoietic and lymphoid tissues (2001), IARC Press, Lyon
37. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
38. Rosati S., Anastasi J., and Vardiman J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Seminars in Hematology 33 (1996) 111-126
39. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. The New England Journal of Medicine 352 (2005) 549-557
40. Janssen J.W., Buschle M., Layton M., et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 73 (1989) 248-254
41. Jaju R.J., Jones M., Boultwood J., et al. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q-syndrome. Genes, Chromosomes & Cancer 29 (2000) 276-280
42. Pfeilstocker M., Reisner R., Nosslinger T., et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. British Journal of Haematology 106 (1999) 455-463
43. Giagounidis A.A., Germing U., Haase S., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18 (2004) 113-119
44. Lai J.L., Preudhomme C., Zandecki M., et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 9 (1995) 370-381
45. Jaju R.J., Boultwood J., Oliver F.J., et al. Molecular cytogenetic delineation of the critical deleted region in the 5q-syndrome. Genes, Chromosomes & Cancer 22 (1998) 251-256
46. Boultwood J., Fidler C., Strickson A.J., et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 99 (2002) 4638-4641
47. Bench A.J., Nacheva E.P., Hood T.L., et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 19 (2000) 3902-3913
48. Virchow R. Weisses blut. Froiep's Notzien 36 (1845) 151
49. Tefferi A., Schad C.R., Pruthi R.K., et al. Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia. Cancer Genetics and Cytogenetics 83 (1995) 61-64
50. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
51. de Klein A., van Kessel A.G., Grosveld G., et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300 (1982) 765-767
52. Groffen J., Stephenson J.R., Heisterkamp N., et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36 (1984) 93-99
53. Heisterkamp N., Stam K., Groffen J., et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315 (1985) 758-761
54. Stam K., Heisterkamp N., Grosveld G., et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. The New England Journal of Medicine 313 (1985) 1429-1433
55. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233 (1986) 212-214
56. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
57. Kelliher M.A., McLaughlin J., Witte O.N., and Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proceedings of the National Academy of Sciences of the USA 87 (1990) 6649-6653
58. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
59. Pendergast A.M., Muller A.J., Havlik M.H., et al. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66 (1991) 161-171
60. Sattler M., Salgia R., Okuda K., et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 12 (1996) 839-846
61. McLaughlin J., Chianese E., and Witte O.N. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proceedings of the National Academy of Sciences of the USA 84 (1987) 6558-6562
62. Voncken J.W., Kaartinen V., Pattengale P.K., et al. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 86 (1995) 4603-4611
63. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Research 56 (1996) 100-104
64. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 2 (1996) 561-566
65. Schindler T., Bornmann W., Pellicena P., et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
66. Shah N.P., Tran C., Lee F.Y., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
67. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
68. Clarkson B., Strife A., Wisniewski D., et al. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 17 (2003) 1211-1262
69. Wilson M.B., Schreiner S.J., Choi H.J., et al. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 21 (2002) 8075-8088
70. Raskind W.H., Jacobson R., Murphy S., et al. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. The Journal of Clinical Investigation 75 (1985) 1388-1390
71. Anger B., Janssen J.W., Schrezenmeier H., et al. Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia 4 (1990) 258-261
72. Tsukamoto N., Morita K., Maehara T., et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. British Journal of Haematology 86 (1994) 253-258
73. el Kassar N., Hetet G., Li Y., et al. Clonal analysis of haemopoietic cells in essential thrombocythaemia. British Journal of Haematology 90 (1995) 131-137
74. Elkassar N., Hetet G., Briere J., and Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia-Advantages of studying T lymphocytes and platelets. Blood 89 (1997) 128-134
75. Shih L.Y., Lin T.L., Dunn P., et al. Clonality analysis using X-chromosome inactivation patterns by HUMARA- PCR assay in female controls and patients with idiopathic thrombocytosis in Taiwan. Experimental Hematology 29 (2001) 202-208
76. Harrison C.N., Gale R.E., Machin S.J., and Linch D.C. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93 (1999) 417-424
77. Chiusolo P., La Barbera E.O., Laurenti L., et al. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Experimental Hematology 29 (2001) 670-676
78. Bacher U., Haferlach T., Kern W., et al. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Annals of Hematology (2005)
79. Sessarego M., Defferrari R., Dejana A.M., et al. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genetics and Cytogenetics 43 (1989) 57-65
80. Steensma D.P., and Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematologica 108 (2002) 55-65
81. Tefferi A., and Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Reviews 15 (2001) 121-131
82. Ash R.C., Detrick R.A., and Zanjani E.D. In vitro studies of human pluripotential hematopoietic progenitors in polycythemia vera. Direct evidence of stem cell involvement. The Journal of Clinical Investigation 69 (1982) 1112-1118
83. Kralovics R., Guan Y., and Prchal J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experimental Hematology 30 (2002) 229-236
84. Beckman B., Anderson W.F., Beltran G., et al. Mixed myeloid-lymphoid colonies in a patient with polycythemia vera. American Journal of Hematology 12 (1982) 419-423
85. Price C.M., Kanfer E.J., Colman S.M., et al. Simultaneous genotypic and immunophenotypic analysis of interphase cells using dual-color fluorescence: a demonstration of lineage involvement in polycythemia vera. Blood 80 (1992) 1033-1038
86. Zamora L., Espinet B., Florensa L., et al. Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients?. Cancer Genetics and Cytogenetics 151 (2004) 139-145
87. Najfeld V., Montella L., Scalise A., and Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. British Journal of Haematology 119 (2002) 558-566
88. Gribble S.M., Reid A.G., Bench A.J., et al. Molecular cytogenetics of polycythaemia vera: lack of occult rearrangements detectable by 20q LSP screening, CGH, and M-FISH. Leukemia 17 (2003) 1419-1421
89. Chen Z., Notohamiprodjo M., Guan X.Y., et al. Gain of 9p in the pathogenesis of polycythemia vera. Genes, Chromosomes & Cancer 22 (1998) 321-324
90. Westwood N.B., Gruszka-Westwood A.M., Atkinson S., and Pearson T.C. Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization. Haematologica 86 (2001) 464-469
91. Kralovics R., Buser A.S., Teo S.S., et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102 (2003) 1869-1871
92. Pellagatti A., Vetrie D., Langford C.F., et al. Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Research 63 (2003) 3940-3944
93. Kralovics R., Stockton D.W., and Prchal J.T. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 102 (2003) 3793-3796
94. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clinic Proceedings 78 (2003) 174-194
95. Engel W., Merker H., Schneider G., and Wolf U. Clonal occurrence of a chromosome Dq-in myelosclerosis with myeloid metaplasia. Humangenetik 6 (1968) 335-337
96. Kahn A., Bernard J.F., Cottreau D., et al. Gd (-) Abrami: a deficient G-6PD variant with hemizygous expression in blood cells of a woman with primary myelofibrosis. Humangenetik 30 (1975) 41-46
97. Kreipe H., Jaquet K., Felgner J., et al. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 78 (1991) 1814-1817
98. Ruutu T., Partanen S., and Knuutila S. Clonal karyotype abnormalities in erythroid and granulocyte-monocyte precursors in polycythaemia vera and myelofibrosis. Scandinavian Journal of Haematology 31 (1983) 253-256
99. Sugiyama H., Ichiba S., Okuno Y., et al. Cytogenetic evidence for a clonal disorder involving CFU-GEMM, BFU-E and CFU-C in patients with myeloproliferative disorders. Nippon Ketsueki Gakkai Zasshi Acta Haematologica Japonica 52 (1989) 1022-1032
100. Greenberg B.R., Woo L., Veomett I.C., et al. Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. British Journal of Haematology 66 (1987) 487-490
101. Wang J.C., Lang H.D., Lichter S., et al. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. British Journal of Haematology 80 (1992) 184-188
102. Buschle M., Janssen J.W., Drexler H., et al. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 2 (1988) 658-660
103. Tefferi A., Mesa R.A., Schroeder G., et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. British Journal of Haematology 113 (2001) 763-771
104. Reilly J.T., Snowden J.A., Spearing R.L., et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. British Journal of Haematology 98 (1997) 96-102
105. Tefferi A. Myelofibrosis with myeloid metaplasia. The New England Journal of Medicine 342 (2000) 1255-1265
106. Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clinic Proceedings 80 (2005) 75-83
107. Sanada I., Asou N., Kojima S., et al. Acute myelogenous leukemia (FAB M1) associated with t(5;16) and eosinophilia. Report of an additional case. Cancer Genetics and Cytogenetics 43 (1989) 139-141
108. Blatt P.M., Rothstein G., Miller H.L., and Cathey W.J. Loffler's endomyocardial fibrosis with eosinophilia in association with acute lymphoblastic leukemia. Blood 44 (1974) 489-493
109. Keung Y.K., Beaty M., Steward W., et al. Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genetics and Cytogenetics 138 (2002) 139-142
110. Kuroda J., Kimura S., Akaogi T., et al. Myelodysplastic syndrome with clonal eosinophilia accompanied by eosinophilic pulmonary interstitial infiltration. Acta Haematologica 104 (2000) 119-123
111. Wilkinson K., Velloso E.R., Lopes L.F., et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 102 (2003) 4187-4190
112. Ma S.K., Kwong Y.L., Shek T.W., et al. The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Human Pathology 30 (1999) 864-868
113. Yam L.T., Yam C.F., and Li C.Y. Eosinophilia in systemic mastocytosis. American Journal of Clinical Pathology 73 (1980) 48-54
114. Bain B.J. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. American Journal of Hematology 77 (2004) 82-85
115. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. British Journal of Haematology 121 (2003) 203-223
116. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood 102 (2003) 3093-3096
117. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. The New England Journal of Medicine 347 (2002) 481-487
118. Cross N.C., and Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16 (2002) 1207-1212
119. Trempat P., Villalva C., Laurent G., et al. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec. Oncogene 22 (2003) 5702-5706
120. Baxter E.J., Hochhaus A., Bolufer P., et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics 11 (2002) 1391-1397
121. Safley A.M., Sebastian S., Collins T.S., et al. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes, Chromosomes & Cancer 40 (2004) 44-50
122. Cools J., Stover E.H., Boulton C.L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 3 (2003) 459-469
123. Griffin J.H., Leung J., Bruner R.J., et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proceedings of the National Academy of Sciences of the USA 100 (2003) 7830-7835
124. Pardanani A., Brockman S.R., Paternoster S.F., et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104 (2004) 3038-3045
125. Vandenberghe P., Wlodarska I., Michaux L., et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18 (2004) 734-742
126. Klion A.D., Robyn J., Akin C., et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103 (2004) 473-478
127. Pardanani A., Brockman S.R., Li C.-Y., et al. FIP1L1-PDGFRA fusion in eosinophilia-associated disorders: prevalence and clinicopathologic correlates. Blood 102 (2003) 146a [Abstract#503]
128. Golub T.R., Barker G.F., Lovett M., and Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
129. Ross T.S., Bernard O.A., Berger R., and Gilliland D.G. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91 (1998) 4419-4426
130. Magnusson M.K., Meade K.E., Brown K.E., et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 98 (2001) 2518-2525
131. Kulkarni S., Heath C., Parker S., et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Research 60 (2000) 3592-3598
132. Schwaller J., Anastasiadou E., Cain D., et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 97 (2001) 3910-3918
133. Abe A., Emi N., Tanimoto M., et al. Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 90 (1997) 4271-4277
134. Steer E.J., and Cross N.C. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta. Acta Haematologica 107 (2002) 113-122
135. Baxter E.J., Kulkarni S., Vizmanos J.L., et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. British Journal of Haematology 120 (2003) 251-256
136. Granjo E., Lima M., Lopes J.M., et al. Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach. A case report. Acta Haematologica 107 (2002) 108-112
137. Gupta R., Knight C.L., and Bain B.J. Receptor tyrosine kinase mutations in myeloid neoplasms. British Journal of Haematology 117 (2002) 489-508
138. Grand F.H., Burgstaller S., Kuhr T., et al. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Research 64 (2004) 7216-7219
139. Carroll M., Tomasson M.H., Barker G.F., et al. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proceedings of the National Academy of Sciences of the USA 93 (1996) 14845-14850
140. Ross T.S., and Gilliland D.G. Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein. The Journal of Biological Chemistry 274 (1999) 22328-22336
141. Wilbanks A.M., Mahajan S., Frank D.A., et al. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Experimental Hematology 28 (2000) 584-593
142. Meyer J., Laker C., Janzir N., et al. Activation of the gene for the PDGF receptor beta1 (PDGFRbeta) in interleukin-3-dependent myeloid cells by retroviral insertional mutagenesis: implications for the transforming potential of PDGFRbeta. Growth Factors 20 (2002) 131-140
143. Tomasson M.H., Williams I.R., Hasserjian R., et al. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 93 (1999) 1707-1714
144. Akin C., Kirshenbaum A.S., Semere T., et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Experimental Hematology 28 (2000) 140-147
145. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nature Genetics 12 (1996) 312-314
146. Akin C., Fumo G., Yavuz A.S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103 (2004) 3222-3225
147. Pignon J.M., Giraudier S., Duquesnoy P., et al. A new c-kit mutation in a case of aggressive mast cell disease. British Journal of Haematology 96 (1997) 374-376
148. Pardanani A., Reeder T.L., Kimlinger T.K., et al. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leukemia Research 27 (2003) 739-742
149. Buttner C., Henz B.M., Welker P., et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. The Journal of Investigative Dermatology 111 (1998) 1227-1231
150. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proceedings of the National Academy of Sciences of the USA 92 (1995) 10560-10564
151. Furitsu T., Tsujimura T., Tono T., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. The Journal of Clinical Investigation 92 (1993) 1736-1744
152. Kitayama H., Tsujimura T., Matsumura I., et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 88 (1996) 995-1004
153. Ma Y., Carter E., Wang X., et al. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. The Journal of Investigative Dermatology 114 (2000) 392-394
154. Ferrao P.T., Gonda T.J., and Ashman L.K. Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. Leukemia Research 27 (2003) 547-555
155. Chian R., Young S., Danilkovitch-Miagkova A., et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 98 (2001) 1365-1373
156. Ning Z.Q., Li J., and Arceci R.J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 97 (2001) 3559-3567
157. Hashimoto K., Matsumura I., Tsujimura T., et al. Necessity of tyrosine 719 and phosphatidylinositol 3′-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 101 (2003) 1094-1102
158. Shivakrupa R., Bernstein A., Watring N., and Linnekin D. Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Research 63 (2003) 4412-4419
159. Jelacic T., and Linnekin D. PKC{delta} plays opposite roles in growth mediated by wild-type kit and an oncogenic kit mutant. Blood (2004)
160. Piao X., Paulson R., van der Geer P., et al. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proceedings of the National Academy of Sciences of the USA 93 (1996) 14665-14669
161. Tanaka A., Konno M., Muto S., et al. A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood (2004)
162. Longley Jr. B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proceedings of the National Academy of Sciences of the USA 96 (1999) 1609-1614
163. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99 (2002) 1741-1744
164. Zermati Y., De Sepulveda P., Feger F., et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22 (2003) 660-664
165. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Experimental Hematology 31 (2003) 686-692
166. Aguiar R.C., Chase A., Coulthard S., et al. Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood 90 (1997) 3130-3135
167. Macdonald D., Reiter A., and Cross N.C. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematologica 107 (2002) 101-107
168. Fioretos T., Panagopoulos I., Lassen C., et al. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes, Chromosomes & Cancer 32 (2001) 302-310
169. Guasch G., Popovici C., Mugneret F., et al. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood 101 (2003) 286-288
170. Sohal J., Chase A., Mould S., et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes, Chromosomes & Cancer 32 (2001) 155-163
171. Still I.H., Chernova O., Hurd D., et al. Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11. Blood 90 (1997) 3136-3141
172. Xiao S., Nalabolu S.R., Aster J.C., et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nature Genetics 18 (1998) 84-87
173. Smedley D., Somers G., Venter D., et al. Characterization of a t(8;13)(p11;q11-12) in an atypical myeloproliferative disorder. Genes, Chromosomes & Cancer 21 (1998) 70-73
174. Chaffanet M., Popovici C., Leroux D., et al. t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12. Oncogene 16 (1998) 945-949
175. Smedley D., Hamoudi R., Clark J., et al. The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Human Molecular Genetics 7 (1998) 637-642
176. Popovici C., Adelaide J., Ollendorff V., et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proceedings of the National Academy of Sciences of the USA 95 (1998) 5712-5717
177. Reiter A., Sohal J., Kulkarni S., et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 92 (1998) 1735-1742
178. Kulkarni S., Reiter A., Smedley D., et al. The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome. Genomics 55 (1999) 118-121
179. Rosati R., La Starza R., Veronese A., et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 99 (2002) 3857-3860
180. Aguiar R.C., Macdonald D., Mason P.J., et al. Myeloproliferative disorder associated with 8p11 translocations. Blood 86 (1995) 834-835
181. Nakayama H., Inamitsu T., Ohga S., et al. Chronic myelomonocytic leukaemia with t(8;9)(p11;q34) in childhood: an example of the 8p11 myeloproliferative disorder?. British Journal of Haematology 92 (1996) 692-695
182. van den Berg H., Kroes W., van der Schoot C.E., et al. A young child with acquired t(8;9)(p11;q34): additional proof that 8p11 is involved in mixed myeloid/T lymphoid malignancies. Leukemia 10 (1996) 1252-1253
183. Belloni E., Trubia M., Gasparini P., et al. 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes, Chromosomes & Cancer 42 (2005) 320-325
184. Popovici C., Zhang B., Gregoire M.J., et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 93 (1999) 1381-1389
185. Vizmanos J.L., Hernandez R., Vidal M.J., et al. Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. The Hematology Journal 5 (2004) 534-537
186. Grand E.K., Grand F.H., Chase A.J., et al. Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes, Chromosomes & Cancer 40 (2004) 78-83
187. Roumiantsev S., Krause D.S., Neumann C.A., et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 5 (2004) 287-298
188. Chen J., DeAngelo D.J., Kutok J.L., et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proceedings of the National Academy of Sciences of the USA 101 (2004) 14479-14484
189. Demiroglu A., Steer E.J., Heath C., et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 98 (2001) 3778-3783
190. Elliott M.A., Hanson C.A., Dewald G.W., et al. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia 19 (2005) 313-317
191. Bohm J., and Schaefer H.E. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. Journal of Clinical Pathology 55 (2002) 862-864
192. Pane F., Frigeri F., Sindona M., et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88 (1996) 2410-2414
193. Bohm J., Kock S., Schaefer H.E., and Fisch P. Evidence of clonality in chronic neutrophilic leukaemia. Journal of Clinical Pathology 56 (2003) 292-295
194. Yanagisawa K., Ohminami H., Sato M., et al. Neoplastic involvement of granulocytic lineage, not granulocytic-monocytic, monocytic, or erythrocytic lineage, in a patient with chronic neutrophilic leukemia. American Journal of Hematology 57 (1998) 221-224
195. Choi I.K., Kim B.S., Lee K.A., et al. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report. American Journal of Hematology 77 (2004) 366-369
196. Oliver J.W., Deol I., Morgan D.L., and Tonk V.S. Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genetics and Cytogenetics 107 (1998) 111-117
197. Chusid M.J., Dale D.C., West B.C., and Wolff S.M. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54 (1975) 1-27
198. Fauci A.S., Harley J.B., Roberts W.C., et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Annals of Internal Medicine 97 (1982) 78-92
199. Chang H.W., Leong K.H., Koh D.R., and Lee S.H. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 93 (1999) 1651-1657
200. Roufosse F., Schandene L., Sibille C., et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. British Journal of Haematology 109 (2000) 540-548
201. Raghavachar A., Fleischer S., Frickhofen N., et al. T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. Journal of Immunology 139 (1987) 3753-3758
202. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. British Journal of Haematology 33 (1976) 451-458
203. Breccia M., Latagliata R., Mengarelli A., et al. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. Haematologica 89 (2004) 866-868
204. Onida F., and Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Current Hematology Reports 3 (2004) 218-226
205. Onida F., Kantarjian H.M., Smith T.L., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99 (2002) 840-849
206. Cytogenetics of chronic myelomonocytic leukemia. Cancer Genetics and Cytogenetics 1986;21:11-30.
207. Magnusson M.K., Meade K.E., Nakamura R., et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 100 (2002) 1088-1091
208. Gunby R.H., Cazzaniga G., Tassi E., et al. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematologica 88 (2003) 408-415
209. Cuneo A., Tomasi P., Ferrari L., et al. Cytogenetic analysis of different cellular populations in chronic myelomonocytic leukemia. Cancer Genetics and Cytogenetics 37 (1989) 29-37
210. Shimada H., Mori T., Shimasaki N., et al. Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia. Leukemia 18 (2004) 1142-1144
211. Cooper L.J., Shannon K.M., Loken M.R., et al. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood 96 (2000) 2310-2313
212. Nakazawa T., Koike K., Agematsu K., et al. Cytogenetic clonality analysis in monosomy 7 associated with juvenile myelomonocytic leukemia: clonality in B and NK cells, but not in T cells. Leukemia Research 22 (1998) 887-892
213. Emanuel P.D. Juvenile myelomonocytic leukemia. Current Hematology Reports 3 (2004) 203-209
214. Tartaglia M., Niemeyer C.M., Fragale A., et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics 34 (2003) 148-150
215. Side L.E., Emanuel P.D., Taylor B., et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 92 (1998) 267-272
216. Loh M.L., Vattikuti S., Schubbert S., et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103 (2004) 2325-2331
217. Largaespada D.A., Brannan C.I., Jenkins N.A., and Copeland N.G. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nature Genetics 12 (1996) 137-143
218. Gitler A.D., Kong Y., Choi J.K., et al. Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia. Pediatric Research 55 (2004) 581-584
219. Emanuel P.D., Snyder R.C., Wiley T., et al. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 95 (2000) 639-645
220. Locatelli F., Nollke P., Zecca M., et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 105 (2005) 410-419
221. Korthof E.T., Snijder P.P., de Graaff A.A., et al. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. Bone Marrow Transplantation (2005)
222. Pardanani A., Baek J.Y., Li C.Y., Butterfield J.H., and Tefferi A. Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. Mayo Clinic Proceedings 77 (2002) 1169-1175
223. Miranda R.N., Esparza A.R., Sambandam S., and Medeiros L.J. Systemic mast cell disease presenting with peripheral blood eosinophilia. Human Pathology 25 (1994) 727-730
224. Baek J.Y., Tefferi A., Pardanani A., and Li C.Y. Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease. Leukemia Research 26 (2002) 83-90
225. Horny H.P., and Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leukemia Research 25 (2001) 543-551
226. Pardanani A., Kimlinger T.K., Reeder T.L., et al. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. British Journal of Haematology 120 (2003) 691-694
227. Del Canizo M.C., Brufau A., Mota A., et al. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders. Haematologica 83 (1998) 3-7
228. Kurzrock R., Bueso-Ramos C.E., Kantarjian H., et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. Journal of Clinical Oncology 19 (2001) 2915-2926
229. Aurich J., Duchayne E., Huguet-Rigal F., et al. Clinical, morphological, cytogenetic and molecular aspects of a series of Ph-negative chronic myeloid leukemias. Hematology and Cell Therapy 40 (1998) 149-158
230. Mancini M., Scappaticci D., Cimino G., et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood (2005)
231. Bagg A. Role of molecular studies in the classification of lymphoma. Expert Review of Molecular Diagnostics 4 (2004) 83-97
232. Schlenk R.F., Benner A., Krauter J., et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German acute myeloid leukemia intergroup. Journal of Clinical Oncology 22 (2004) 3741-3750